Today, on 29 April, the JSC Grindeks submitted the audited consolidated financial statements of 2015 to Nasdaq Riga. Audited financial results indicate that the Group’s...
JSC Grindeks, the manufacturer of Mildronate® (meldonium), has submitted an open letter to the World Anti-Doping Agency (WADA). According to the JSC Grindeks, WADA has...
There’s really no evidence that there’s any performance enhancement from meldonium, said Don Catlin, a long-time anti-doping expert and the scientific director of the Banned...
Despite Grindeks submitted arguments, evidence and justifications, the World Anti-Doping Agency (WADA) included meldonium in the Prohibited list. In accordance with the results of the...
Today, on 26 February, the JSC Grindeks submitted the non-audited consolidated financial statements of 2015 to Nasdaq Riga. Non-audited financial results indicate that the Group’s...
JSC Grindeks will publish its: non-audited financial statement for the 12-month period of 2015 on February 26, 2016; non-audited interim financial statement for the 3-month...
Today, on 27 November, the JSC Grindeks submitted the non-audited consolidated financial statements for the nine months of 2015 to “Nasdaq Riga”. Non-audited financial results...
From 13th to 15th of October, 2015, Grindeks and its subsidiary “Kalceks” participate in the leading pharmaceutical exhibition “CPhI Worldwide 2015” in Madrid, Spain. During...